Centro médico privado Cemaic

Córdoba X5008HHW

2 studies enrolling now · 6 studies all time

What they study most

Advanced Non-small Cell Lung Cancer, HER2 Mutation, Biliary Tract Cancer, Diabetes Mellitus, Diabetes Mellitus, Type 2, Metastatic Renal Cell Carcinoma, Neoplasm Metastasis, Obesity, Overweight, Renal Cell Carcinoma, Urinary Bladder Neoplasm

Studies at this site

• AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight — Recruiting now
• Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer — Recruiting now
• A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) — Recruiting now
• A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes — Completed
• A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC) — Stopped early
• A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer — Completed